Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study
| Autor: | Lubina Arjyal, Abesh Niroula, Amir Bista, Syed Imran Mustafa Jafri, Adithya Chennamadhavuni, Angela L. Smith, Dipesh Uprety |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Skin Neoplasms Adolescent Population Antineoplastic Agents Ipilimumab Dermatology Young Adult 03 medical and health sciences 0302 clinical medicine Internal medicine Epidemiology medicine Humans Molecular Targeted Therapy 030212 general & internal medicine Young adult education Melanoma Survival rate Neoplasm Staging Retrospective Studies education.field_of_study business.industry Proportional hazards model Hazard ratio Retrospective cohort study Middle Aged Survival Rate Treatment Outcome 030220 oncology & carcinogenesis Female business Follow-Up Studies SEER Program medicine.drug |
| Zdroj: | Melanoma Research. 28:56-60 |
| ISSN: | 0960-8931 |
| DOI: | 10.1097/cmr.0000000000000394 |
| Popis: | In 2011, ipilimumab was approved by the US Food and Drug Administration (FDA) for metastatic melanoma. Since its approval, numerous targeted therapies have been approved by the FDA. Population-based studies assessing the survival benefit from these agents are lacking. We therefore carried out this study to compare the 1-year, 2-year, and median overall survival (OS) among metastatic melanoma patients in pretargeted and post-targeted eras. This is a retrospective study that utilized the Surveillance, Epidemiology, and End Results (SEER-18) database, version 8.3.4 (22 March 2017). The patient groups were defined as the pretargeted era (2004-2010) and the post-targeted era (2011-2014) as ipilimumab was approved by the FDA in 2011. The database comprised of 5471 patients (3314 in the pretargeted era and 2157 in the post-targeted era). OS in the post-targeted era was found to be significantly better compared with the pretargeted era by Kaplan-Meier curve (1-year OS: 38.9 vs. 36.8%, 2-year OS: 28.3 vs. 23.5%, and median survival: 8 vs. 7 months, P=0.001 by the log-rank test). The survival was significantly better in the post-targeted era compared with the pretargeted era on multivariate analysis using a Cox proportional hazard model after adjusting for age, sex, race, and metasectomy status (adjusted hazard ratio of 0.889, 95% CI: of 0.832-0.951, P=0.001). There is significant survival benefit in metastatic melanoma patients since the introduction of immune checkpoint-blocking agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|